Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives.

Autor: Vathiotis IA; Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece; Department of Pathology, Yale University School of Medicine, New Haven, CT. Electronic address: ioannis.vathiotis@yale.edu., Trontzas I; Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece., Gavrielatou N; Department of Pathology, Yale University School of Medicine, New Haven, CT., Gomatou G; Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece., Syrigos NK; Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece., Kotteas EA; Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Attica, Greece.
Jazyk: angličtina
Zdroj: Clinical breast cancer [Clin Breast Cancer] 2022 Oct; Vol. 22 (7), pp. 642-649. Date of Electronic Publication: 2022 Jul 07.
DOI: 10.1016/j.clbc.2022.06.004
Abstrakt: Anti-programmed cell death protein 1 immunotherapy has been incorporated in the treatment algorithm of triple-negative breast cancer (TNBC). However, clinical trial results for patients with hormone receptor (HR)-positive disease appear less compelling. HR-positive tumors exhibit lower levels of programmed death-ligand 1 expression in comparison with their triple-negative counterparts. Moreover, signaling through estrogen receptor alters the immune microenvironment, rendering such tumors immunologically "cold." To explain differential responses to immune checkpoint blockade, this review interrogates differences between HR-positive and TNBC. Starting from distinct genomic features, we further present disparities concerning the tumor microenvironment and finally, we summarize early-phase clinical trial results on promising novel immunotherapy combinations.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: